Replacement hormonal therapy in men: practical aspects


Cite item

Full Text

Abstract

References

  1. Katz A., Burchill C. Androgen therapy: testing before prescribing and monitoring during therapy. Can. Fam. Physician 2007; 53: 1936-1942.
  2. Moncada I. Testosterone and men's quality of life. Aging Male 2006; 9: 189-193.
  3. Bhasin S., Cunningham G. R., Hayes F. J. et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J. Clin. Endocrinol. 2006; 91: 1995-2010.
  4. Travison T. G., Morley J. E., Araujo A. В., et al. The relationship between libido and testosterone levels in aging men. J. Clin. Endocrinol. 2006; 91: 2509-2513.
  5. Morley J. E., Charlton E., Patrick P. et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239-1242.
  6. Moore С., Huebler D., Zimmermann Т. et al. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur. Urol. 2004; 46: 80-87.
  7. Wang C., Nieschlag E., Swerdloff R. et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur. Urol. 2009; 55: 121-130.
  8. Diver M. J., Imtiaz K. E., Ahmad A. M., et al. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin. Endocrinol. (Oxford) 2003; 58: 710-717.
  9. de Ronde W., van der Schouw Y. T., Pols H. A. et al. Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms. Clin. Chem. 2006; 52: 1777-1784.
  10. Citron J. T., Ettinger В., Rubinoff H. et al. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. J. Urol. (Baltimore) 1996; 155: 529- 533.
  11. Zitzmann M., Faber S., Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J. Clin. Endocrinol. 2006; 91: 4335-4343.
  12. Hajjar R. R., Kaiser F. E., Morley J. E. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J. Clin. Endocrinol. 1997; 82: 3793-3796.
  13. Gerstenbluth R. E., Maniam P. N., Corty E. W., Seftel A. D. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J. Androl. 2002; 23: 922-926.
  14. Calof O. M., Singh A. B., Lee M. L., et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J. Geronto. A. Biol. Sci. Med. Sci. 2005; 60: 1451-1457.
  15. Dipl. Med. Jens Jacobeit Internist/Endokrinologe, Endokrinolodikum. Hamburg.
  16. Bagatell C. J. , Bremner W. J. Androgen and progestagen effects on plasma lipids. Progn. Colardiovasc. Dis. l995; 38: 255-271.
  17. Dobs A. S., Matsumoto A. M., Wang C., Kipnes M. S. Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. Curr. Med. Res. Opin. 2004; 20: 729-738.
  18. Stuenkel C. A., Dudley R. E., Yen S. S. Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. J. Clin. Endocrinol. 1991; 72: 1054-1059.
  19. Wang C., Cunningham G., Dobs A. et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J. Clin. Endocrinol. 2004; 89: 2085-2098.
  20. Kelleher S., Howe C., Conway A. J., Handelsman D. J. Testosterone release rate and duration of action of testosterone pellet implants. Clin. Endocrinol. (Oxford) 2004; 60: 420-428.
  21. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin. Endocrinl. (Oxford) 2006; 65: 275- 28l.
  22. Gooren L. J., Bunck M. C. Androgen replacement therapy: present and future. Drugs 2004; 64: 1861-1891.
  23. Nieschlag E., Buchter D., Von Eckardstein S., et al. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin. Endocrinol. (Oxford) 1999; 51: 757-763.
  24. Yassin A. A., Haffejee M. Testosterone depot injection in male hypogonadism: a critical appraisal. Clin. Interv. Aging 2007; 2: 577-590.
  25. Shabsigh R., Kaufman J. M., Steidle C., Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J. Urol. (Baltimore) 2004; 172: 658-663.
  26. Аляев Ю. Г., Винаров А. З., Ахвледиани Н. Д. Выбор лечебной тактики при эректильной дисфункции, ассоциированной с гипогонадизмом. Урология 2010; 4: 37-42.
  27. Yassin A. A., Saad F., Traish A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J. Sex. Med. 2006; 3: 727-735.
  28. Kapoor D., Goodwin E.,, Channer KS, Jones T. H. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur. J. Endocrinol. 2006; 154: 899-906.
  29. English K. M., Steeds R. I., Jones T. H. et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 2000; 102: 1906-1911.
  30. Malkin C. J., Pugh P. J., West J. N. et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur. Heart J. 2006; 27: 57- 64.
  31. Cherrier M. M., Craft S., Matsumoto A. H. Cognitive changes associated with supplementation of testosterone or dihydrotestosterone in mildly hypogonadal men: a preliminary report. J. Androl. 2003; 24: 568-576.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies